These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 19680295)

  • 1. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
    Pérez-Soler R
    Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized medicine in oncology: tailoring the right drug to the right patient.
    Jiang Y; Wang M
    Biomark Med; 2010 Aug; 4(4):523-33. PubMed ID: 20701441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC.
    Hirsch FR
    Oncogene; 2009 Aug; 28 Suppl 1():S1-3. PubMed ID: 19680291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.
    Eberhard DA; Giaccone G; Johnson BE;
    J Clin Oncol; 2008 Feb; 26(6):983-94. PubMed ID: 18281673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
    Crawford J
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular predictors of chemotherapy response in non-small-cell lung cancer.
    Gray J; Simon G; Bepler G
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):545-9. PubMed ID: 17428174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating new targeted agents into the treatment of non-small-cell lung cancer.
    Thatcher N
    Lung Cancer; 2006 Dec; 54 Suppl 2():S25-31. PubMed ID: 17056150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel targeted therapies for non-small cell lung cancer.
    Smith PW; Denlinger CE; Jones DR
    Thorac Surg Clin; 2006 Nov; 16(4):353-66. PubMed ID: 17240823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular markers in the treatment of metastatic colorectal cancer.
    Wilson PM; Labonte MJ; Lenz HJ
    Cancer J; 2010; 16(3):262-72. PubMed ID: 20526105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiling of non-small-cell lung cancer.
    Lacroix L; Commo F; Soria JC
    Expert Rev Mol Diagn; 2008 Mar; 8(2):167-78. PubMed ID: 18366303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The biology of non-small-cell lung cancer: identifying new targets for rational therapy.
    Rosell R; Felip E; Garcia-Campelo R; Balaña C
    Lung Cancer; 2004 Nov; 46(2):135-48. PubMed ID: 15474661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
    Burris HA
    Oncogene; 2009 Aug; 28 Suppl 1():S4-13. PubMed ID: 19680296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer.
    Rothschild SI; Gautschi O; Lara PN; Mack PC; Gandara DR
    Curr Opin Oncol; 2011 Mar; 23(2):150-7. PubMed ID: 21119513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: a riddle, wrapped in a mystery, inside an enigma.
    Shepherd FA; Tsao MS
    J Clin Oncol; 2010 Feb; 28(6):903-5. PubMed ID: 20100955
    [No Abstract]   [Full Text] [Related]  

  • 16. Evolution of therapy decision-making process for advanced non-small cell lung cancer.
    Gebbia V; Mancuso G; Lombardi L; Maiello E
    Oncology; 2009; 77 Suppl 1():97-102. PubMed ID: 20130437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic medicine in non-small cell lung cancer: paving the path to personalized care.
    Sriram KB; Larsen JE; Yang IA; Bowman RV; Fong KM
    Respirology; 2011 Feb; 16(2):257-63. PubMed ID: 21044232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects for molecular staging of non-small-cell lung cancer from genomic alterations.
    Tomaszek SC; Huebner M; Wigle DA
    Expert Rev Respir Med; 2010 Aug; 4(4):499-508. PubMed ID: 20658911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomics in non-small-cell lung cancer chemotherapy.
    Danesi R; Pasqualetti G; Giovannetti E; Crea F; Altavilla G; Del Tacca M; Rosell R
    Adv Drug Deliv Rev; 2009 May; 61(5):408-17. PubMed ID: 19292993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in genomic and proteomic studies of non-small-cell lung cancer: clinical and translational research perspective.
    Dziadziuszko R; Hirsch FR
    Clin Lung Cancer; 2008 Mar; 9(2):78-84. PubMed ID: 18501093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.